Trial Profile

A Clinical trial of LNR 653.1

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 08 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LNR 653.1 (Primary)
Indications Diabetic macular oedema; Psoriasis; Retinal vein occlusion; Wet age-related macular degeneration
Focus Adverse reactions
Sponsors Lanier Biotherapeutics

Most Recent Events

08 Oct 2021 New trial record
05 Oct 2021 According to a Lanier Biotherapeutics media release, the company plans to initiate investigational new drug (IND) enabling studies of LNR 653.1 in 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com